Quick summary

Eucommia ulmoides is a traditional Chinese medicinal plant extensively studied for its potential bone-protective and cardiovascular benefits. Preclinical and some preliminary clinical evidence suggest it may support bone health by promoting osteoblastogenesis and inhibiting osteoclastogenesis, with additional possible roles in hypertension management and metabolic regulation. Its bioactive components include iridoids, flavonoids, lignans, and polysaccharides. However, high-quality, large-scale clinical trials are limited, and safety data in humans remain insufficient.

What is it

Eucommia ulmoides, commonly known as Eucommia or Hardy Rubber Tree, is a deciduous tree native to China. It has been used in traditional Chinese medicine (TCM) for centuries. Various parts of the plant, especially its bark and leaves, are utilized for their potential medicinal properties. Eucommia is noted for its bioactive compounds such as iridoids, flavonoids, lignans, and polysaccharides.

Traditional uses

In traditional Chinese medicine, Eucommia has been used primarily to support the musculoskeletal system, particularly for strengthening bones and tendons. It is also traditionally utilized to promote general vitality and address hypertension and related cardiovascular concerns. Eucommia is frequently included in multi-herb formulations aimed at managing ailments like osteoporosis, hypertension, and kidney deficiency.

Active compounds

  • Iridoids
  • Flavonoids
  • Lignans
  • Polysaccharides
  • Chlorogenic acid (noted for antioxidant and antihypertensive effects)

Potential benefits with evidence levels

Bone health and osteoporosis management

Evidence level: Preclinical and limited clinical evidence

Systematic reviews and meta-analyses of animal studies suggest that Eucommia extracts may improve bone mineral density, trabecular microarchitecture, and biomechanical strength. These effects appear related to promotion of osteoblast differentiation and inhibition of osteoclastogenesis via multiple molecular pathways such as ERK/BMP-2/SMAD, BMP/SMAD, Wnt/β-catenin, OPG/RANKL, and MAPK/NF-κB. Preliminary human studies report improved bone mineral density and reduced bone resorption markers in osteoporotic patients. There is some indication that combining Eucommia with Western medicines like bisphosphonates may enhance outcomes, though the quality of evidence varies and is often low.

Cardiovascular and metabolic effects

Evidence level: Limited clinical and preclinical evidence

Randomized controlled trials in skeletal fluorosis patients have suggested that TCM formulations containing Eucommia combined with lifestyle modifications may reduce cardiovascular metabolic risk factors such as blood pressure and LDL cholesterol. The presence of chlorogenic acid in Eucommia contributes to documented antioxidant and antihypertensive effects in preclinical models.

Neuroprotection and anti-aging

Evidence level: Preclinical evidence

Studies in Caenorhabditis elegans models indicate that Eucommia leaf extracts may prolong lifespan and improve healthspan markers via MAPK signaling and mitochondrial homeostasis. Additional research suggests potential neuroprotective effects through anti-inflammatory and antioxidant mechanisms, although clinical data are lacking.

Side effects

Current human clinical trials report no serious adverse events directly attributed to Eucommia or Eucommia-containing formulations. Mild and transient side effects are possible but not well-characterized. Preclinical safety data are favorable. However, systematic safety evaluations and toxicity studies in humans remain limited, and long-term safety data are lacking.

Drug interactions

No specific studies or clinical data on drug interactions involving Eucommia ulmoides have been identified in the available literature. Caution is advised when combining with pharmaceuticals until more information becomes available.

Who should avoid it

Due to insufficient safety data, Eucommia should be used with caution or avoided in special populations such as pregnant or breastfeeding women. No explicit contraindications have been reported in reviewed studies, but standard precautions apply, especially given the limited evidence base.

Evidence limitations

  • Most clinical evidence comes from TCM formulations containing Eucommia combined with other herbs, complicating attribution of effects specifically to Eucommia.
  • Human clinical trials are generally limited by small sample sizes, methodological weaknesses, and short follow-up periods.
  • High heterogeneity and risk of bias exist in available studies, limiting the reliability of effect size estimates.
  • Lack of large-scale, randomized, placebo-controlled clinical trials focusing solely on Eucommia ulmoides.
  • Safety and toxicity data in humans are insufficient, including lack of information on drug interactions and use during pregnancy and lactation.

References

Last reviewed

June 2024

Informational disclaimer

This page is for informational purposes only and does not constitute medical advice. The described benefits and uses are based on current scientific evidence, which is limited and not conclusive. Always consult a qualified healthcare provider before starting any new herbal supplement, especially if you are pregnant, breastfeeding, have existing health conditions, or are taking medications.